DexCom Inc (OQ:DXCM)

Business Focus: Medical Equipment, Supplies & Distribution

Apr 25, 2024 04:03 pm ET

Dexcom Reports First Quarter 2024 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.

Apr 03, 2024 09:00 am ET

Dexcom Publishes Annual Sustainability Report

DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on key corporate sustainability initiatives that are aligned with Dexcom’s core values and business strategy.

Apr 02, 2024 08:30 am ET

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Mar 05, 2024 04:26 pm ET

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose biosensor that doesn’t require a prescription. There are approximately 25 million people in the U.S. living with Type 2 diabetes who do not use insulin and wh

Mar 05, 2024 01:20 pm ET

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and data will be presented during Dexcom sym

Mar 05, 2024 03:00 am ET

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

Feb 27, 2024 04:05 pm ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th.

Feb 08, 2024 04:02 pm ET

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.

Jan 23, 2024 08:30 am ET

Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference

Jan 19, 2024 02:00 am ET

Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new state-of-the-art manufacturing facility, located in Athenry, Co. Galway. This marks the first step in the realisation of this facility, which will bring more than 1,000 jobs to the area and repr

Jan 15, 2024 03:30 am ET

A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2™ insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa. The announcement comes just a month after the syste

Jan 08, 2024 08:00 am ET

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2023 to be at least $1.030 billion, an increase of 26% over the fourth quarter of 2022. U.S. revenue is expected to be approximately $765 million, representing

Dec 19, 2023 08:30 am ET

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare Conference on January 8, 2024.

Dec 06, 2023 01:06 pm ET

Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes,

Dec 06, 2023 08:40 am ET

Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes,

Nov 21, 2023 08:30 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29th.

Nov 14, 2023 12:01 am ET

Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) systems for people with diabetes, is teaming up with

Nov 08, 2023 04:00 am ET

Historic Victory as People With Diabetes Win Access to Life-Changing Technology, But Almost Half Don’t Understand the Benefits1-2

DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today new market research which found 79% of people struggle to keep their glucose levels in range, and that almost half (45%) don’t understand what a Hybrid Closed Loop System (HCL) is or how HCL could benefit them1-2. Findings also showed that 99% of healthcare providers expect the NICE TA for HCL systems will somewhat or significantly help change the lives of people living with type 1 diabetes for the better1-2.

Oct 27, 2023 09:31 am ET

Thinking about buying stock in Bitfarms, Mullen Automotive, SeaStar Medical Holding, NKGen Biotech, or DexCom?

NEW YORK, Oct. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BITF, MULN, ICU, NKGN, and DXCM.

Oct 26, 2023 04:03 pm ET

Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2023.

Oct 05, 2023 08:30 am ET

Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant. Its introduction brings the most accurate CGM on the market*,1 to Canadians, offering users a new way to gain greater control of their diabetes.

Oct 02, 2023 02:00 am ET

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Ass

Sep 29, 2023 08:30 am ET

Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, October 26, 2023. Management will hold a conference call to review the company's third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast

Sep 21, 2023 08:30 am ET

Dexcom Canada and RxFood Corporation Partner on Industry-Leading, AI-powered Nutrition and Glucose Monitoring Solution for Diabetes Management and Personalized Therapeutic Nutrition

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, and RxFood Corporation, the leader in AI-driven personalized nutrition assessments, announced today a first-of-its-kind partnership in Canada to introduce an improved digital health solution for those living with diabetes

Sep 19, 2023 06:00 am ET

Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of the second season of

Sep 12, 2023 04:00 am ET

Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced the availability of its Dexcom ONE real-time CGM sensor via reimbursement, in France.

Sep 01, 2023 04:00 am ET

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System With a New Aid Offering in Germany

DexCom, Inc. (Nasdaq: DXCM), global manufacturer of systems for real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) is the first and only CGM to connect to the Omnipod 5 AID System in Germany, helping users to protect against high and low glucose levels.

Aug 30, 2023 08:30 am ET

Dexcom Announces Upcoming Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:

Aug 28, 2023 08:30 am ET

Dexcom Appoints Rimma Driscoll to Board of Directors

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023.

Aug 15, 2023 08:30 am ET

Dexcom Canada Achieves Great Place to Work® Certification for Second Consecutive Year

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that for the second consecutive year, it has been certified as a Great Place to Work® in Canada for 2023-24. Awarded by Great Place to Work Institute®, the global authority on workplace culture, this certification is based on direct feedback from employees about their workplace experience, and the sentiment of pride they feel in representing Dexcom.

Jul 27, 2023 04:03 pm ET

Dexcom Reports Second Quarter 2023 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2023.

Jul 06, 2023 08:30 am ET

Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call to review the company's second quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Jul 04, 2023 08:30 am ET

Dexcom G7 Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System With Unmatched Accuracy Coming to Canadians

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that Health Canada has approved the next-generation Dexcom G7 Continuous Glucose Monitoring System for people with all types of diabetes, ages two years and older.

Jun 23, 2023 08:15 pm ET

Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people living with diabetes, announced today its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured at the 83rd Scientific Sessions of the American Diabetes Associat

Jun 23, 2023 08:00 pm ET

Dexcom Updates Long-Range Financial Targets

DexCom, Inc. (NASDAQ:DXCM) today announced an update to its long-range financial targets at its 2023 Investor Day. Based on the company’s strong performance in the first two years of the target period, Dexcom is updating its year-end 2025 financial targets to the following levels:

Jun 21, 2023 04:00 am ET

Dexcom G6 Strengthens Its Position as World’s Most Connected CGM System

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Real-Time Continuous Glucose Monitoring System (rt-CGM) is the first and only CGM to connect to the Omnipod® 5 AID System, helping users to protect against high and low glucose levels1,2.

Jun 12, 2023 04:00 am ET

New Study Shows That 84% of People With Diabetes Struggle With Mental Health1

As the UK marks the start of Diabetes Awareness Week, a new study reveals 84% of people surveyed agree having diabetes can negatively impact mental health.1 The study, commissioned by DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, also found that nearly all those living with

Jun 08, 2023 08:30 am ET

Dexcom to Host Investor Day on June 23, 2023

DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations from Dexcom management highlighting the company’s market opportunities, business strategy, innovation efforts, and long-term financial outlook.

Jun 01, 2023 08:30 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7th.

May 10, 2023 06:30 pm ET

Dexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66th Annual Meeting of the Japan Diabetes Society

DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the accuracy, reliability and ease of use of its Dexcom G6 CGM System and will highlight the latest clinical evidence that continues to demonstrate the effectiveness of Dexcom CGM during the 66th Annual Me

May 03, 2023 07:00 am ET

Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $1.0 billion. Dexcom also granted the initial purchasers of the notes an option to purchase, within a 13-day period from, and

May 03, 2023 04:00 am ET

Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a study “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK” in Diabete

May 02, 2023 07:00 am ET

Dexcom Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes

DexCom, Inc. (Nasdaq: DXCM) (“Dexcom”) announced today that it intends to offer, subject to market conditions and other factors, $1.0 billion aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Dexcom also intends to grant the initial purchasers of the notes an option to purchase, within a 13-day period from, and including, the date on which the notes are first issued, up to an additional

Apr 27, 2023 04:03 pm ET

Dexcom Reports First Quarter 2023 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2023.

Apr 27, 2023 06:00 am ET

Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds the progressive expansion of coverage for continuous glucose monitoring systems through the Non-Insured Health Benefits (NIHB) program. Following an announcement made earlier this year, this decision further broadens the coverage criteria, now enabling any client managing diabetes with insulin to access the standard of care.

Apr 17, 2023 08:00 am ET

Dexcom Commends Decision to Expand CGM Medicare Coverage to Include People With Diabetes Using All Types of Insulin

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to include people with diabetes using all types of insulin, as well as certain non-insulin-using individuals who have a history of problematic hypoglycemic events.* The updated Med

Apr 06, 2023 05:30 am ET

Dexcom Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2023 financial results after market close on Thursday, April 27, 2023. Management will hold a conference call to review the company's first quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Apr 05, 2023 09:00 am ET

Dexcom Publishes Annual Sustainability Report

DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report, which provides updates on key environmental, social, and governance (ESG) initiatives that are aligned with Dexcom’s core values and business strategy.

Mar 21, 2023 06:00 am ET

Manitoba Becomes a Provincial Trailblazer in Providing Simplified Access to Advanced Glucose Monitors

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced that its Dexcom G6 CGM System will be available to people of all ages with type 1 and type 2 diabetes in Manitoba who meet eligibility criteria.

Mar 13, 2023 07:30 am ET

DexCom Comments on SVB Relationship

DexCom, Inc. (NASDAQ: DXCM), today issued the following statement in response to speculation following the developments at Silicon Valley Bank, including a recent CNBC article:

Feb 23, 2023 09:00 am ET

Dexcom Announces Upcoming Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences:

Feb 22, 2023 12:00 am ET

Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase the strength of its CGM portfolio and unveil new clinical and real-world evidence that continues to demonstrate the effectiveness of Dexcom CGM at the 16th International Conference on Advanced Technologies and Trea

Feb 21, 2023 08:54 pm ET

Dexcom G6 Continuous Glucose Monitoring System Launches in Singapore

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of its Dexcom G6 CGM System in Singapore for people with diabetes ages two years and older, including pregnant women, and the appointment of DKSH Singapore Pte Ltd as sales, marketing, and distribution service pro

Feb 13, 2023 08:30 am ET

Dexcom G7 Continuous Glucose Monitoring System Will Be Available to Medicare Beneficiaries at Launch

Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System will be covered for Medicare beneficiaries.† Having met the category requirements for therapeutic CGM systems set forth by the U.S. Centers for Medicare & Medicaid Ser

Feb 09, 2023 04:03 pm ET

Dexcom Reports Fourth Quarter and Fiscal Year 2022 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2022.

Feb 07, 2023 09:25 am ET

Dexcom and Nick Jonas Make Super Bowl Magic to Launch New Dexcom G7 Continuous Glucose Monitoring System

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today unveiled the company’s second

Jan 24, 2023 09:00 am ET

Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a conference call to review the company's fourth quarter and full year 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference cal

Jan 17, 2023 06:00 am ET

Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits (NIHB) Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness.

Jan 09, 2023 08:00 am ET

Dexcom Appoints Teri Lawver as Chief Commercial Officer

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief commercial officer. In this role, Ms. Lawver will oversee the global commercial organization with responsibility for global sales, marketing and customer expe

Jan 09, 2023 08:00 am ET

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic1 basis. U.S. revenue

Jan 03, 2023 09:00 am ET

Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023.

Dec 12, 2022 08:00 am ET

Dexcom Canada Partners With Green Shield and The Health Depot to Offer Plan Members a Comprehensive Digital Diabetes Care Experience

Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (rtCGM), announced today its partnership with Green Shield and The Health Depot digital pharmacy to provide Green Shield plan members with convenient access to the Dexcom G6 rtCGM System combined with virtual diabetes coaching support.

Dec 08, 2022 08:45 am ET

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all Types of diabetes ages two years and older.

Dec 08, 2022 08:36 am ET

Thinking about trading options or stock in Prometheus Biosciences, Apple, Chevron, DexCom, or Amazon?

NEW YORK, Dec. 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RXDX, AAPL, CVX, DXCM, and AMZN.

Nov 30, 2022 11:25 am ET

Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers

Dexcom, Inc. (NASDAQ: DXCM), - November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile innovative strategies for prevention and management. In this context, Dexcom Canada is pleased to announce its participation in the Truckers’ Health Adaptive Technology (T.H.A.T.) project, as a digital heath technology partner, in support of improving health and safety outcomes of professional truck drivers with the introduction of real-time, data-guided virtual care and coaching.

Nov 22, 2022 09:00 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that Matt Dolan, Executive Vice President, Strategy, Corporate Development and Dexcom Labs, will present an update on the company at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 8:30am (EST).

Nov 14, 2022 04:00 am ET

Dexcom Invites the Diabetes Community to #seediabetes This November and Share Their Diabetes Story With Custom Continuous Glucose Monitor (CGM) Patches

DexCom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring, its global partners and Dexcom Warriors will once again help the world #SeeDiabetes and empower members of the diabetes community to express their unique journey with diabetes in an accessible way – by creating custom Dexcom CGM patches via the newly launched design

Nov 01, 2022 09:00 am ET

Dexcom Partners With Warriors and Nonprofits to Artfully Advocate for Access to Diabetes Care

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes will come together with members of the diabetes community during National Diabetes Awareness Month and World Diabetes Day to give people with diabetes a creative way to share their stories through the #SeeDiabetes campaign.

Oct 28, 2022 09:31 am ET

Thinking about trading options or stock in Amazon, Twitter, DexCom, Advanced Micro Devices, or Exxon Mobil?

NEW YORK, Oct. 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMZN, TWTR, DXCM, AMD, and XOM.

Oct 27, 2022 04:03 pm ET

Dexcom Reports Third Quarter 2022 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2022.

Oct 24, 2022 08:00 am ET

Dexcom, Adam Schefter Announce Dexcom U, the First NIL Program for College Athletes With Diabetes

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of

Oct 07, 2022 08:32 am ET

Thinking about buying stock in Invivo Therapeutics, Credit Suisse, Hexo, Payoneer Global, or DexCom?

NEW YORK, Oct. 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVIV, CS, HEXO, PAYO, and DXCM.

Oct 04, 2022 03:00 am ET

Dexcom G7 Launches in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System is now available for people with diabetes age two years and older in the UK, Ireland, Germany, Austria and Hong Kong – marking the first major milestone in the availab

Sep 29, 2022 09:00 am ET

Dexcom Schedules Third Quarter 2022 Earnings Release and Conference Call for October 27, 2022 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2022 financial results after market close on Thursday, October 27, 2022. Management will hold a conference call to review the company's third quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast

Sep 01, 2022 04:15 pm ET

Dexcom Announces Upcoming Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences:

Aug 31, 2022 05:00 pm ET

DexCom Promotes Jake Leach to Chief Operating Officer

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the promotion of Jake Leach to the role of chief operating officer.

Aug 03, 2022 04:15 pm ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 10:30am (EST).

Aug 01, 2022 07:00 pm ET

Dexcom ONE real-time Continuous Glucose Monitoring (rt-CGM) System available on prescription in the UK, improving access to rt-CGM for people with diabetes

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, and NHS England today announced the availability of the easy to use Dexcom ONE rt-CGM System on prescription via the NHS England, Wales, Scotland and Northern Ireland drug tariff to everyone with type 1 or type 2 diabetes using insulin. This

Jul 28, 2022 04:03 pm ET

Dexcom Reports Second Quarter 2022 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2022.

Jul 27, 2022 08:45 am ET

Dexcom G6 Continuous Glucose Monitoring System Mobile App Now Available in Spanish

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of the Dexcom G6 mobile app in Spanish, available immediately for users with a compatible iOS (v1.10.1) or Android (v1.10.0) smart device.

Jul 19, 2022 06:00 am ET

Dexcom Canada Achieves Great Place to Work® Certification

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring (rtCGM), is proud to announce that it is certified as a Great Place to Work® in Canada for 2022-23. Awarded by Great Place to Work Institute® Canada, the global authority on high-trust, high-performance workplace cultures, this prestigious certification is based on direct feedback from employees and demonstrates Dexcom’s commitment to fostering a workplace culture rooted in transparency, respect, fairness, pride and camaraderie. This year, 92 per cent of employees said they feel proud to tell others they wor

Jun 30, 2022 04:04 pm ET

Dexcom Schedules Second Quarter 2022 Earnings Release and Conference Call for July 28, 2022 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2022 financial results after market close on Thursday, July 28, 2022. Management will hold a conference call to review the company's second quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Jun 02, 2022 08:30 am ET

Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Scientific Sessions of the American Diabetes Association

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase its expanded global portfolio of real-time continuous glucose monitoring (CGM) systems at the 82nd Scientific Sessions of the American Diabetes Association (ADA) conference held in New Orleans and virtually, June 3-

Jun 01, 2022 06:00 am ET

Prince Edward Island Becomes a National Leader in Providing Coverage for Dexcom G6 Continuous Glucose Monitoring System for Canadians With Diabetes

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), announced today that people with type 1 and type 2 diabetes age two and over on multiple daily injections of insulin (three or more) or who use an insulin pump may now be eligible for public coverage of the Dexcom G6 CGM System through Prince Edward Island’s Diabetes Glucose Sensor Program.

May 31, 2022 08:30 am ET

Dexcom Issues Statement on Recent Market Speculation

DexCom, Inc. (NASDAQ:DXCM) today issued the following statement in response to recent media and market speculation:

May 23, 2022 08:00 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that Brice Bobzien, Senior Vice President, Finance, will present an update on the company at the Piper Sandler Ophthalmology and Diabetes Symposium on Wednesday, May 25, 2022 at 1:00 p.m. (EDT).

May 10, 2022 08:00 am ET

Dexcom Announces Upcoming Conference Presentations

Apr 28, 2022 05:27 pm ET

Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time

DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time). The link to the webcast will be available on the DexCom, Inc. investor relations website at

Apr 28, 2022 04:03 pm ET

Dexcom Reports First Quarter 2022 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022.

Apr 26, 2022 02:00 am ET

DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring (CGM) systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30,

Apr 07, 2022 08:45 am ET

Dexcom Publishes Annual Sustainability Report

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its third annual Sustainability Report. This report highlights Dexcom’s mission-driven efforts and provides updates on the environmental, social, and governance (ESG) initiatives progressing across the organization.

Apr 01, 2022 03:29 am ET

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new Dexcom ONE Continuous Glucose Monitoring System will launch in the United Kingdom this May. The Dexcom ONE system is an easy-to-use real-time CGM (rt-CGM) that will be more affordable and accessible for people with di

Mar 31, 2022 04:15 pm ET

Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022. Management will hold a conference call to review the company's first quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Mar 25, 2022 09:00 am ET

Dexcom Announces Four-for-One Forward Stock Split

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split (the “Stock Split”) of Dexcom’s common stock.

Mar 14, 2022 01:39 pm ET

Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark (Conformité Européenne) for the Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with diabetes in Europe age two years and older, including pregnant women.

Mar 14, 2022 03:30 am ET

Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management

Mar 07, 2022 06:00 am ET

Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring System under the Assistive Devices Program

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), is pleased to announce that effective March 14 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program (ADP) for people in the province living with type 1 diabetes who are over 2 years of ag

Mar 01, 2022 04:05 pm ET

FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the FDA has granted Breakthrough Device Designation for Dexcom CGM use in the hospital setting.

Feb 14, 2022 08:45 am ET

Dexcom Announces Upcoming Virtual Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences:

Feb 10, 2022 04:03 pm ET

Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2021.

Feb 03, 2022 05:19 pm ET

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and Youth Living With Diabetes

Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes who are under 18 years old and require ongoing use of insulin or insulin pump therapy are eligible for public coverage of the Dexcom G6 CGM System through Alberta Health.

Jan 24, 2022 08:45 am ET

Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022. Management will hold a conference call to review the company's fourth quarter and full year 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference ca

Jan 10, 2022 07:45 am ET

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial

DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2021 to be approximately $698 million, an increase of 23% over the fourth quarter of 2020. U.S. revenue is expected to be approximately $517 million, represent

Jan 04, 2022 08:45 am ET

Dexcom to Present at 40th Annual J.P. Morgan Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022.

Nov 29, 2021 08:45 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:

Nov 01, 2021 08:45 am ET

Dexcom, Nick Jonas, Patti LaBelle and The Global Movement for Time in Range Invite the World to #SeeDiabetes This November

Dexcom, Inc. (NASDAQ:DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, its nonprofit partners and members of the diabetes community are banding together to help people with diabetes feel more seen and heard this November for National Diabetes Awareness Month and World Diabetes Day.

Oct 28, 2021 04:02 pm ET

Dexcom Reports Third Quarter 2021 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2021.

Oct 05, 2021 08:45 am ET

Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2021 financial results after market close on Thursday, October 28, 2021. Management will hold a conference call to review the company's third quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast

Sep 29, 2021 06:00 am ET

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People With Type 1 Diabetes

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM), is happy to share that people with type 1 diabetes who are 25 years of age or under may now be eligible for provincial coverage of the Dexcom G6 CGM System through Manitoba Health and Seniors Care.

Sep 13, 2021 01:00 pm ET

Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy

Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), is pleased to announce the Dexcom G6 CGM System is now covered by the Non-Insured Health Benefits (NIHB) Program for people living with diabetes who are between 2 and 19 years old and require intensive insulin therapy. This expanded coverage will give more First Nations and Inuit children and adolescents access to this standard of care, potentially helping them to have more control over a life-long chronic illness.

Sep 02, 2021 08:45 am ET

Dexcom Announces Upcoming Virtual Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:

Jul 29, 2021 04:02 pm ET

Dexcom Reports Second Quarter 2021 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2021.

Jul 15, 2021 04:51 pm ET

FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring

Jul 07, 2021 08:45 am ET

Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2021 financial results after market close on Thursday, July 29, 2021. Management will hold a conference call to review the company's second quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Jun 25, 2021 08:45 am ET

Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today featured research and data presentations that will headline the 81st Scientific Sessions of the American Diabetes Association (ADA) virtual conference held June 25-29, 2021.

Jun 24, 2021 10:00 am ET

DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the launch of

Jun 22, 2021 09:14 am ET

Endurance Athlete Sébastien Sasseville to Ride Across Canada in Support of JDRF’s Access For All Campaign

Dexcom, Inc. and Tandem Diabetes Care, Inc. are thrilled to announce their support of

Jun 11, 2021 01:28 pm ET

British Columbia First Province to Cover Dexcom G6 Continuous Glucose Monitoring System for People With Type 1 and Type 2 Diabetes on Intensive Insulin Therapy

Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes who are on intensive insulin therapy, age two years or older, may now be eligible for provincial coverage of the Dexcom G6 CGM System through BC PharmaCare. This coverage expansion is in line with Dexcom’s mission to make it easier for people living with diabetes to experience the benefits of using a CGM system for their diabetes management.

Jun 03, 2021 11:11 am ET

Dexcom Looks to the Future of Continuous Glucose Monitoring

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the publication and presentation of two new studies during the 14th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).

Jun 01, 2021 06:00 am ET

Saskatchewan Health to Cover Dexcom G6 Continuous Glucose Monitoring System for People with Diabetes under the age of 18

Dexcom CGM use is proven to improve glycemic control1,2 and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.3 BURNABY, BC, June 1, 2021 /CNW Telbec/ - Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), announced today that people with diabetes under the age of 18 living in Saskatchewan may now receive provincial coverage for the Dexcom G6 CGM System through Saskatchewan Health. This coverage expansion is in line with Dexcom's mission to make it easier for people living with diabetes to experience

May 27, 2021 08:45 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

May 26, 2021 06:00 am ET

RAMQ Now Offers Provincial Coverage of The Dexcom G6 Continuous Glucose Monitoring System for People Living with Type 1 Diabetes in Quebec

Proven to improve glycemic control and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring.1 BURNABY, BC, May 26, 2021 /CNW Telbec/ - Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), announced today that people living with type 1 diabetes, age two years or older, may now receive provincial coverage for the Dexcom G6 CGM System by the Régie de l'Assurance Maladie du Quebec (RAMQ). This coverage expansion is in line with Dexcom's mission to make it easier for people living with diabetes in Quebec to e

Apr 29, 2021 04:02 pm ET

Dexcom Reports First Quarter 2021 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2021.

Apr 20, 2021 09:00 am ET

Dexcom G6 CGM System Approved for Back of Upper Arm Wear, Offering Adults with Diabetes Greater Freedom

Dexcom G6 gives people with diabetes the power to manage their condition without fingersticks* or scanning Proven to improve glycemic control and can reduce the risk of costly long-term diabetes-related complications compared to fingerstick monitoring1 BURNABY, BC, April 20, 2021 /CNW/ - Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), today announced the company has received Health Canada authorization for the Dexcom G6 CGM System to be worn on the back of the upper arm by adults 18 and older. The new indication will give adult users more ways to comf

Apr 16, 2021 04:56 pm ET

Manitoba and Saskatchewan Promise to Make Life-Changing Dexcom G6 CGM System Accessible for Children and Young Adults with Type 1 Diabetes

Dexcom G6 gives people with diabetes the power to manage their condition without fingersticks* or scanning BURNABY, BC, April 16, 2021 /CNW/ - Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), is pleased to see that the governments of Saskatchewan and Manitoba both recognized in their budgets last week CGM for children and young adults living with diabetes.

Apr 01, 2021 04:15 pm ET

Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2021 financial results after market close on Thursday, April 29, 2021. Management will hold a conference call to review the company's first quarter 2021 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Mar 23, 2021 08:30 am ET

Dexcom Promotes Jereme Sylvain to Chief Financial Officer

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Jereme Sylvain to the role of Executive Vice President and Chief Financial Officer. In his expanded role, Mr. Sylvain will assume responsibility for Dexcom’s entire finance organization and report to Quentin Blackford, Chief Operat

Feb 17, 2021 08:45 am ET

Dexcom Announces Upcoming Virtual Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences:

Feb 11, 2021 04:10 pm ET

Dexcom Launches Inaugural Venture Capital Fund

DexCom, Inc. (Nasdaq: DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the launch of Dexcom Ventures. The inaugural fund will seek to identify and invest in opportunities to supplement growth in the core business and advance the development of adjacent technologies for the future.

Feb 11, 2021 04:02 pm ET

Dexcom Reports Fourth Quarter and Fiscal Year 2020 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2020.

Feb 02, 2021 10:00 am ET

Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial, Calling for Better Care for People With Diabetes

DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, debuted today its

Jan 19, 2021 08:30 am ET

Dexcom Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call for February 11, 2021 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2020 financial results after market close on Thursday, February 11, 2020. Management will hold a conference call to review the company's fourth quarter and full year 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference ca

Jan 11, 2021 07:30 am ET

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook

Jan 05, 2021 08:30 am ET

Dexcom to Present at 39th Annual J.P. Morgan Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39th annual J.P. Morgan Healthcare Conference on January 11, 2021.

Dec 08, 2020 05:08 am ET

Diabetes Awareness Month review: patients in Quebec and Canada have legitimate expectations

BURNABY, BC, Dec. 8th, 2020 /CNW Telbec/ - Following the end of Diabetes Awareness Month, Dexcom is highlighting the legitimate expectations of patients with this chronic disease and their families regarding continuous glucose monitoring systems. The pandemic caused by COVID-19 has increased the challenges associated with diabetes management, but governments have technologies at their disposal that help achieve optimal quality of care for patients.

Nov 12, 2020 08:45 am ET

Dexcom Announces Upcoming Virtual Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:

Nov 03, 2020 10:18 am ET

Dexcom to Host Investor Day on December 9, 2020

DexCom, Inc. (NASDAQ:DXCM) announced today that it will host an Investor Day on December 9, from 8:30 AM until approximately 11:30 AM Pacific Standard Time (11:30 AM – 2:30 PM Eastern). The event, which will be held virtually, will include presentations from Dexcom management and industry leaders highlighting the company’s market opportunities, business

Nov 03, 2020 08:30 am ET

Dexcom to Host Investor Day on December 9, 2020

Oct 27, 2020 04:03 pm ET

Dexcom Reports Third Quarter 2020 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2020.

Oct 26, 2020 04:42 pm ET

Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue

DexCom, Inc. (NASDAQ:DXCM) today announced that Rick Doubleday, Executive Vice President and Chief Commercial Officer, will retire at the end of 2020 in order to spend more time with his family. Rick joined Dexcom in 2009 and has built a world-class sales organization that allowed Dexcom to grow from approximately $49 million in reported revenue in his

Oct 13, 2020 08:30 am ET

Dexcom Appoints Kyle Malady to Board of Directors

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Kyle Malady to its Board of Directors, effective immediately.

Oct 01, 2020 08:30 am ET

Dexcom Schedules Third Quarter 2020 Earnings Release and Conference Call for October 27, 2020 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2020 financial results after market close on Tuesday, October 27, 2020. Management will hold a conference call to review the company's third quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast.

Sep 24, 2020 08:30 am ET

Dexcom Signs Multi-Year Collaboration Agreement with the University of Virginia to Advance Type 1 and Type 2 Diabetes Research

DexCom, Inc. (NASDAQ:DXCM) today announced it has signed a five-year collaboration agreement with the University of Virginia to advance its research and development efforts on continuous glucose monitoring-based solutions. The research partnership will center on advancing Dexcom’s automated insulin delivery technology and exploring the use of continuous

Sep 22, 2020 08:30 am ET

Dexcom G6 Continuous Glucose Monitoring System Now Available at Veterans Affairs Pharmacies Across the United States

DexCom, Inc. (NASDAQ:DXCM) announced today the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now

Sep 16, 2020 08:30 am ET

Dexcom Announces First-Ever Registry Dedicated to Tracking Outcomes of In-Hospital Real-Time CGM Use in Response to the COVID-19 Pandemic

DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (rtCGM) for people with d

Sep 04, 2020 08:45 am ET

Dexcom Announces Upcoming Virtual Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:

Aug 12, 2020 08:30 am ET

Dexcom Appoints Karen Dahut to Board of Directors

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.

Aug 10, 2020 04:05 pm ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

Jul 28, 2020 04:03 pm ET

Dexcom Reports Second Quarter 2020 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2020.

Jul 16, 2020 10:18 am ET

Health Canada Authorizes Interim Use of Dexcom G6 CGM by Pregnant Women in Response to the COVID-19 Pandemic

TORONTO, July 16, 2020 /CNW/ - Last week, Health Canada temporarily authorized the adjunctive use of the Dexcom G6 Continuous Glucose Monitoring (CGM) system by pregnant women with Type 1, Type 2, or gestational diabetes. This temporary expanded indication was granted because of the active role Dexcom CGM can play in the treatment and mitigation of COVID-19 by significantly reducing the in-person interaction between pregnant women with diabetes and healthcare providers, reducing potential exposure to the virus.

Jun 30, 2020 08:45 am ET

Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to review the company's second quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference.

Jun 04, 2020 09:00 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

May 12, 2020 09:31 am ET

Thinking about buying stock in Overstock.com, Moderna, Royal Caribbean Cruises, DexCom, or Walt Disney?

NEW YORK, May 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSTK, MRNA, RCL, DXCM, and DIS.

May 12, 2020 07:00 am ET

DexCom Prices Offering of Upsized $1.05 Billion of 0.25% Convertible Senior Notes

DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today the pricing of its offering of $1.05 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $850.0 million. DexCom also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $157.5 million aggregate principal amoun

May 11, 2020 07:00 am ET

DexCom Announces Proposed Offering of $850.0 Million of Convertible Senior Notes

DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $850.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $150.0 million aggregate principal amount of notes.

May 08, 2020 05:52 pm ET

DexCom, Inc. Announces Change of Location of Annual Meeting of Stockholders to Be Held May 21, 2020

DexCom, Inc. (NASDAQ:DXCM) today announced that, due to the public health impact of the COVID-19 pandemic, the location of the 2020 Annual Meeting of Stockholders of DexCom, Inc. (the “Company”) has been changed and will be held as a hybrid meeting that stockholders can attend either in person or virtually via live webcast, though the Company strongly encourages stockholders to participate virtually. As previously announced, the Annual Meeting will be held on Thursday, May 21, 2020 at 2:00 p.m. Pacific Time. To be admitted to the virtual Annual Meeting, you must register to attend by May 19, 2

May 07, 2020 09:31 am ET

Thinking about trading stocks or options in DexCom, Fastly, Teva Pharmaceutical, Cars.com, or General Electric?

NEW YORK, May 7, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DXCM, FSLY, TEVA, CARS, and GE.

May 06, 2020 07:23 pm ET

DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600

NEW YORK, May 6, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening on Tuesday, May 12:

May 04, 2020 08:30 am ET

Health Canada Temporarily Authorizes Dexcom G6 CGM for Use in Hospitals to Monitor Critically Ill Patients During COVID-19 Pandemic

TORONTO, May 4, 2020 /CNW/ - Health Canada recently announced the Dexcom G6 Continuous Glucose Monitoring (CGM) system has been temporarily authorized for expanded use in hospitals, in an effort to help remotely monitor those who are critically ill during the COVID-19 pandemic. The remote glucose monitoring* capability of the Dexcom G6 CGM system is expected to reduce caregiver interactions and exposure to COVID-19 in the hospital setting and help to preserve personal protective equipment during the pandemic.

Apr 28, 2020 04:03 pm ET

Dexcom Reports First Quarter 2020 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2020.

Apr 27, 2020 08:00 am ET

Dexcom to Launch Patient Assistance Program for Current U.S. Customers Impacted by COVID-19 Pandemic

DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) systems for people with diabe

Apr 02, 2020 08:30 am ET

Dexcom Schedules First Quarter 2020 Earnings Release and Conference Call for April 28, 2020 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2020 financial results after market close on Tuesday, April 28, 2020. Management will hold a conference call to review the company's first quarter 2020 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at

Feb 24, 2020 04:15 pm ET

Dexcom to Present at Cowen 40th Annual Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:

Feb 19, 2020 07:00 am ET

Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

DexCom, Inc. (NASDAQ: DXCM) and Insulet Corporation (NASDAQ: PODD), have announced a global commercialization agreement to combine current and future Dexcom continuous glucose monitoring systems (CGM) with Insulet’s trusted tubeless insulin delivery Pod into the Omnipod Horizon™ System for automated insulin delivery, currently in pivotal trial. Under

Feb 13, 2020 04:01 pm ET

Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.

Jan 21, 2020 09:00 am ET

Dexcom Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 13, 2020 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2019 financial results after market close on Thursday, February 13, 2020. Management will hold a conference call to review the company's fourth quarter and full year 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. investor relations website at investors.dexcom.com and will be archived there for future reference.

Jan 13, 2020 07:30 am ET

Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook

DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018. U.S. revenue is expected to be approximately $373 million, representing growth of 33% over the fourth quarter of 2018. International revenue is expected to be approximately $84 million, an increase of 47% over the fourth quarter of 2018.

Jan 06, 2020 08:45 am ET

Dexcom to Present at 38th Annual J.P. Morgan Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 38th annual J.P. Morgan Healthcare Conference on January 13, 2020.

Nov 26, 2019 09:00 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conference:

Nov 08, 2019 09:00 am ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

Nov 06, 2019 04:03 pm ET

Dexcom Reports Third Quarter 2019 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019.

Oct 09, 2019 04:47 pm ET

Dexcom Schedules Third Quarter 2019 Earnings Release and Conference Call for November 6, 2019 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2019 financial results after market close on Wednesday, November 6, 2019. Management will hold a conference call to review the company's third quarter 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at

Oct 08, 2019 08:30 am ET

Dexcom Announces FDA Clearance of New Dexcom G6 Pro CGM

Dexcom, Inc. (NASDAQ:DXCM) announced today the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up.

Sep 17, 2019 04:05 pm ET

Dexcom Promotes Quentin Blackford to Chief Operating Officer

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Quentin Blackford to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer.

Sep 17, 2019 08:30 am ET

Dexcom Appoints Bridgette Heller to Board of Directors

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Bridgette Heller to its Board of Directors, effective immediately.

Sep 09, 2019 11:05 am ET

Dexcom G6® CGM System Now Available In Canada

Revolutionary new Continuous Glucose Monitoring System eliminates fingersticks* for people with diabetes

Aug 23, 2019 04:25 pm ET

Court Rules that the Patents Asserted against Dexcom CGM Systems are Invalid

The U.S. District Court for the District of Oregon has granted Dexcom's (NASDAQ:DXCM) motion for summary judgment invalidating all asserted claims in the two remaining patents asserted against it by WaveForm Technologies, Inc., a subsidiary of AgaMatrix.

Aug 02, 2019 08:30 am ET

Dexcom Announces Upcoming Conference Presentations

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conferences:

Jul 31, 2019 04:03 pm ET

Dexcom Reports Second Quarter 2019 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2019.

Jul 02, 2019 09:00 am ET

Dexcom Schedules Second Quarter 2019 Earnings Release and Conference Call for July 31, 2019 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2019 financial results after market close on Wednesday, July 31, 2019. Management will hold a conference call to review the company's second quarter 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at

Jun 06, 2019 08:45 am ET

Dexcom and Companion Medical Announce Collaboration to Integrate Dexcom CGM Data and InPen™ Insulin Data

DexCom, Inc. (NASDAQ:DXCM) and Companion Medical, Inc. today announced a collaboration to enable a direct exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications. This agreement is the first of its kind and paves the way for advanced diabetes decision support, an important tool for insulin users.

May 22, 2019 04:15 pm ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

May 01, 2019 04:02 pm ET

Dexcom Reports First Quarter 2019 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2019.

Apr 03, 2019 04:05 pm ET

Dexcom Schedules First Quarter 2019 Earnings Release and Conference Call for May 1, 2019 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2019 financial results after market close on Wednesday, May 1, 2019. Management will hold a conference call to review the company's first quarter 2019 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at

Mar 21, 2019 01:30 pm ET

Spruce Point Capital Releases A Strong Sell Research Opinion On DexCom, Inc. (NASD: DXCM)

NEW YORK, March 21, 2019 /PRNewswire/ -- Report entitled "Sugar High" outlines how DXCM may face 45%-60% intermediate downside risk to approximately $65 to $85 per share due to the market's significant misunderstanding of the true addressable market of Dexcom's G6 continuous glucose monitor (CGM), Abbot's current dominance even before the launch of the functionally equivalent Libre 2 and the impending growth wall Dexcom will hit in 2020 as a result of its lack of Type 2 targeted product.

Feb 26, 2019 07:25 am ET

Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care — Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Infinera Corporation (NASDAQ:INFN), Alliant Energy Corporation...

Feb 25, 2019 04:15 pm ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

Feb 22, 2019 12:13 pm ET

Dexcom G6® CGM System Receives Health Canada Approval

VANCOUVER, Feb. 22, 2019 /CNW/ - Dexcom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), today announced that the company has received Health Canada approval for its next generation Dexcom G6 CGM System for people with diabetes ages two years and up.

Feb 21, 2019 04:10 pm ET

Dexcom Reports Fourth Quarter and Fiscal Year 2018 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2018.

Jan 24, 2019 04:15 pm ET

Dexcom Schedules Fourth Quarter and Full Year 2018 Earnings Release and Conference Call for February 21, 2019 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2018 financial results after market close on Thursday, February 21, 2019. Management will hold a conference call to review the company's fourth quarter and full year 2018 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the DexCom, Inc. website at

Jan 07, 2019 07:30 am ET

Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2018 and Provides Initial 2019 Outlook

DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2018 to exceed $331 million, an increase of at least 50% over the fourth quarter of 2017. For fiscal 2018, total preliminary, unaudited revenue is expected to exceed $1.025 billion, an increase of more than 42% over 2017.

Dec 18, 2018 04:01 pm ET

Dexcom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

Nov 29, 2018 08:15 am ET

Detailed Research: Economic Perspectives on Broadridge Financial Solutions, MercadoLibre, Rogers, Ensco plc, Liberty Oilfield Services, and DexCom — What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Broadridge Financial Solutions, Inc. (NYSE:BR), MercadoLibre, Inc....

Nov 28, 2018 06:30 am ET

DexCom Prices Offering of $750.0 Million of 0.75% Convertible Senior Notes

DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $100.0 million aggregate principal amount of notes. The sale of the notes is expected to close on November 30, 201

Nov 26, 2018 04:15 pm ET

DexCom Announces Proposed Offering of $750 Million of Convertible Senior Notes

DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $750 million aggregate principal amount of Convertible Senior Notes due 2023 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also intends to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $100 million aggregate principal amount of notes.

Nov 21, 2018 08:30 am ET

DexCom Announces Upcoming Conference Presentation

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

Nov 20, 2018 05:12 pm ET

Dexcom and Verily Amend Collaboration and License Agreement

DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), and Verily, an Alphabet company, an

Nov 07, 2018 05:30 pm ET

Dexcom to Host Investor Day on December 4, 2018

DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on December 4, 2018 at the Laguna Cliffs Marriott in Dana Point, California. The event will include updates on the company’s innovation pipeline, business strategy, and long-term financial outlook.

Nov 06, 2018 04:01 pm ET

DexCom Reports Third Quarter 2018 Financial Results

DexCom, Inc. (Nasdaq: DXCM) today reported its unaudited financial results as of and for the quarter ended September 30, 2018.

Oct 22, 2018 07:45 am ET

Detailed Research: Economic Perspectives on DexCom, MiX Telematics, Resolute Forest Products, Equinix, Johnson & Johnson, and Vedanta — What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DexCom, Inc. (NASDAQ:DXCM), MiX Telematics Limited (NYSE:MIXT), Resolute...

You are here

DexCom Inc (OQ:DXCM)

Business Focus: Medical Equipment, Supplies & Distribution